Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Conditions: Rectal Adenocarcinoma; Circulating Tumor DNA; Minimal Residual Disease; Neoadjuvant Chemoradiotherapy Intervention: Diagnostic Test: MRD detection Sponsors: WeiWei Xiao; Haplox Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Condition: Rectal Cancer Interventions: Radiation: split-course hypofraction radiotherapy; Drug: CAPOX; Drug: Envafolimab; Procedure: Local excision Sponsor: 池畔 Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 1, 2023 Category: Research Source Type: clinical trials
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
Condition: Rectal Cancer Interventions: Drug: Trifluridine/Tipiracil; Radiation: intensity-modulated radiotherapy Sponsor: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 28, 2023 Category: Research Source Type: clinical trials
